plasmin

6-Aminocaproic acid (EACA) is an antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

ZK824190 is an orally available and selective inhibitor of urokinase plasminogen activator (uPA), with IC50 values of 237 nM for uPA, 1600 nM for tPA, and 1850 nM for Plasmin.

ZK824859 is an orally available and selective inhibitor of urokinase plasminogen activator (uPA) with IC50 values of 79 nM for human uPA, 1580 nM for tPA, and 1330 nM for plasmin.

ZK824859 hydrochloride is an oral available and selective inhibitor of urokinase plasminogen activator (uPA)(IC50s of 79 nM, 1580 nM and 1330 nM for human uPA, tPA, and plasmin, respectively).

Alpha 2 Antiplasmin serves as the principal circulating inhibitor of plasmin. This compound plays a crucial role in regulating fibrinolysis within blood vessels.

Plasminogen is a zymogen secreted as a precursor protein that, when cleaved by urokinase plasminogen activator (uPA) or tissue plasminogen activator (tPA), is converted into plasmin. Plasmin is a protease with broad specificity, capable of degrading fibrin and various extracellular matrix (ECM) components. Additionally, plasminogen functions as a proinflammatory regulator, promoting the healing of both acute and diabetic wounds. It is utilized in research related to wound healing, inflammation, and hypoplasminogenemia [1] [2].

Ceruloplasmin is a biochemical reagent used as either a biological material or an organic compound in life sciences research.

Patamostat mesylate (E-3123) is a potent protease inhibitor with IC50 values of 39 nM for trypsin, 950 nM for plasmin, and 1.9 μM for thrombin. This compound demonstrates promising potential in suppressing the pathogenesis and development of acute pancreatitis.

Patamostat HCl is a highly potent and selective small molecule protease (protease) inhibitor that inhibits trypsin, fibrinolytic enzymes, and thrombin with IC50 values of 39 nM, 950 nM, and 1.9 μM, respectively.Patamostat HCl is used in the study of acute pancreatitis.

Benzamidine hydrochloride (Benzamidine HCl) is a reversible inhibitor of serine proteases, including trypsin, plasmin, and thrombin (Ki of 35, 350, and 220 μM, respectively).

Tranexamic acid (Amstat) is an Antifibrinolytic Agent. The physiologic effect of tranexamic acid is by means of Decreased Fibrinolysis.

Rifabutin (LM-427) inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. Rifabutin is a semisynthetic ansamycin antibiotic with potent antimycobacterial properties.

SSR-182289A (Free) is a thrombin inhibitor.

Urokinase peptidolytic,Urokinase-type plasminogen activator (uPA) is a trypsin-like serine protease that exists as an inactive zymogen (pro-uPA) and requires proteolytic cleavage for its activation. once activated, it serves as the central catalyst in a proteolytic cascade that converts plasminogen to plasmin, a process critically involved in physiological and pathological thrombolysis and extracellular matrix degradation.

Upamostat is an inhibitor of a serine protease and is a urokinase plasminogen activator (uPA) inhibitor.

Tiplaxtinin (Tiplasinin)(PAI-039) is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 uM.

SK-216, a specific PAI-1 inhibitor, reduces tumor angiogenesis and inhibits VEGF-induced migration and tube formation of human umbilical vein endothelial cells in vitro. This compound also alleviates bleomycin-induced pulmonary fibrosis in mice.

Aleplasinin (PAZ 417) is a selective and orally active inhibitor of Plasminogen activator inhibitor-1(PAI-1) and a key negative regulator of the fibrinolytic system. Aleplasinin can be used in Alzheimer's disease studies.

UK-371804 is an effective and specific uPA inhibitor. It was selected as a candidate for further preClinicalal evaluation for the treatment of chronic dermal ulcers.

Loureirin B can downregulate the expression of fibrosis-related molecules by regulating MMPs and TIMPs levels, inhibit scar fibroblast proliferation and suppress TGF-β1-induced fibrosis, during which TGF-β1/Smad2/3 pathway is likely involved.

TM5441 is an orally bioavailable fibrinogen activator inhibitor-1 inhibitor that inhibits several cancer cell lines with IC50 values ranging from 13.9 to 51.1 μM.It induces intrinsic cell death in several human cancer cells and attenuates Nω-nitro-1-arginine methyl ester-induced cardiac hypertension and vascular senescence.

TM5275 sodium is a bioactive oral inhibitor of PAI-1 (plasminogen activator inhibitor-1), with an IC50 value of 6.95 μM.

Toddalolactone ((+)-Toddalolactone) is an anti-inflammatory and analgesic.

TM5007 is a poent inhibitor of plasminogen activator inhibitor-1 (PAI-1; IC50 of 29 uM).